Stockpolly
Search
BIOA · NASDAQ · Biotechnology

BioAge Labs (BIOA)

Develops metabolic-disease drug candidates from human-aging biology.

$9.61
Pre-market−0.12 (−1.18%)
At close$9.73(+2.15%)
Watchlist

In millions of USD, except per-share figures

In millionsQ3 FY23Sep 2023Q4 FY23Dec 2023Q1 FY24Mar 2024Q2 FY24Jun 2024Q3 FY24Sep 2024Q4 FY24Dec 2024Q1 FY25Mar 2025Q2 FY25Jun 2025Q3 FY25Sep 2025Q4 FY25Dec 2025Q1 FY26Mar 2026Q2 FY26Jun 2026
Revenue000000122332
Cost of revenue000000000000
Gross profit000000122332
101413152525182725322832
Research & development7109102019112019252024
343556777787
Selling & marketing000000000000
General & administrative343556777787
Operating income−10−14−13−15−25−25−16−25−23−28−25−29
−5−70214433233
Interest income001224433333
Interest expense231000000000
Other non-operating income25−1−2−2−5−4−3−3−3−3−3
Income before tax−15−21−13−14−23−21−13−22−20−26−22−26
Net income from continuing operations−15−21−13−14−23−21−13−22−20−26−22−26
Net income−15−21−13−14−23−21−13−22−20−26−22−26
EPS, basic−$0.43−$0.61−$0.38−$0.40−$0.68−$0.59−$0.36−$0.60−$0.56−$0.72−$0.52−$0.58
EPS, diluted−$0.43−$0.61−$0.38−$0.40−$0.68−$0.59−$0.36−$0.60−$0.56−$0.72−$0.52−$0.58
Weighted average shares, basic343434343436363636364245
Weighted average shares, diluted343434343436363636364245
EBITDA−12−18−12−13−23−21−13−21−20−26−22−26
Depreciation & amortization000000000000
EBIT−12−18−12−13−23−21−13−21−20−26−22−26